男男性行为者口服HIV暴露前预防大型前瞻性实施队列研究(EPIC-NSW)中HIV血清转换者的特征
EPIC-NSW是一项在澳大利亚新南威尔士州开展的口服PrEP实施研究,2016年3月1日至2018年4月30日共入组9596名参与者,至2019年3月31日诊断30例HIV血清转换。血清转换者均未充分依从PrEP,其中19例(63%)合并衣原体、淋病、梅毒或新发丙型肝炎感染,1例检出恩曲他滨耐药(M184V突变)。
要点
- 血清转换者从首次发放PrEP至诊断的中位时间为409天(IQR 347-656)。
- 30例血清转换者中19例(63%)合并衣原体、淋病、梅毒或新发丙型肝炎感染。
- 1例血清转换者在诊断时检出恩曲他滨耐药(M184V突变)。
核心结论
- 血清转换者尽管处于HIV感染高风险,但对PrEP的依从性不足。
- 理解随后感染HIV者PrEP依从性差的原因对提高PrEP有效性至关重要。
研究设计与样本
- EPIC-NSW是一项在澳大利亚新南威尔士州开展的口服PrEP实施研究,纳入年龄≥18岁、HIV感染高风险个体。
- 2016年3月1日至2018年4月30日共入组并发放PrEP 9596名参与者,至2019年3月31日诊断30例HIV血清转换。
- 血清转换定义为入组后抗原、抗体检测阳性或可检测到HIV病毒载量。
- 依从性不足通过发放记录或参与者自我报告评估,定义为每周PrEP剂量<4次。
主要发现
- 30例血清转换者的中位年龄为31岁(IQR 25-38),全部为男性,29例(97%)为男同性恋或同性恋者,20例(69%)居住在男同性恋男性居民浓度低的邮编区。
- 从首次发放PrEP至诊断的中位天数为409天(IQR 347-656)。
- 无证据表明血清转换者曾充分依从PrEP。
- 19例(63%)血清转换者被诊断衣原体、淋病、梅毒或新发丙型肝炎感染。
- 1例血清转换者在诊断时对恩曲他滨耐药(M184V突变)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most human immunodeficiency virus (HIV) seroconversions in people who have initiated preexposure prophylaxis (PrEP) occur in the context of insufficient adherence. We describe participants who seroconverted after being dispensed PrEP in a large PrEP implementation study in Australia. METHODS: Expanded PrEP Implementation in Communities in New South Wales was an implementation study of daily oral PrEP in individuals aged ≥18 years at high risk for acquiring HIV. HIV seroconversions were defined as a positive HIV test by either antigen, antibody, or detectable HIV viral load after enrollment. Insufficient adherence, measured by dispensing logs or participant self-report, was defined as <4 PrEP doses per week. RESULTS: A total of 9596 participants were enrolled and dispensed PrEP between 1 March 2016 and 30 April 2018; 30 were diagnosed with HIV by 31 March 2019. The median (interquartile range [IQR]) age was 31 (25-38) years, all identified as male, 29 (97%) identified as gay or homosexual, and 20 (69%) lived in a postcode with a low concentration of gay male residents. The median (IQR) days from first PrEP dispensing to diagnosis was 409 (347-656). There was no evidence that participants who seroconverted had been sufficiently adherent to PrEP. Nineteen (63%) participants who seroconverted were diagnosed with chlamydia, gonorrhoea, syphilis, or new hepatitis C infection. One participant had resistance to emtricitabine (M184V mutation) at diagnosis. CONCLUSIONS: Participants who seroconverted were insufficiently adherent to PrEP despite being at high risk for acquiring HIV. Understanding the reasons for poor PrEP adherence in individuals who subsequently acquire HIV is critical to improving PrEP effectiveness.
引用
- Dharan NJ, Jin F, Vaccher S, et al. Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW). Clin Infect Dis. 2023. PMID: 35982613. doi:10.1093/cid/ciac660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。